AstraZeneca Announces Major Investment In Ontario Life Sciences Sector

AstraZeneca is pleased to announce it is bringing 500 highly-skilled scientific and high-tech jobs to the Greater Toronto Area (GTA) in a major expansion of its research footprint in Canada. The investment will contribute to AstraZeneca’s Research & Development Hub (R&D) in Mississauga, which focuses on leading global clinical studies in areas including breast, lung and prostate cancer, COVID-19, and chronic kidney disease. It also includes the creation of a new Alexion, AstraZeneca Rare Disease Development Hub, which focuses on rare disease research.

NewsGuest UserMarch 16, 2023BIOOQuébecbiotechnology, Vaccines, therapeutics production, biomanufacturing, Astrazeneca

Government of Canada establishes new research hubs to accelerate Canada’s vaccine and therapeutics production

Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health, announced an investment of $10 million in support of the creation of five research hubs to accelerate Canada’s vaccine and therapeutics production.

NewsGuest UserMarch 16, 2023BIOOQuébecbiotechnology, Vaccines, therapeutics production, biomanufacturing